tetano
Editor, Senior Moderator
PLoS Pathog
. 2022 Sep 19;18(9):e1010782.
doi: 10.1371/journal.ppat.1010782. eCollection 2022 Sep.
SARS-CoV-2-specific immunoglobulin Y antibodies are protective in infected mice
Sherif A El-Kafrawy[SUP] 1 2 [/SUP], Abby Odle[SUP] 3 [/SUP], Aymn T Abbas[SUP] 1 2 4 [/SUP], Ahmed M Hassan[SUP] 1 [/SUP], Umama A Abdel-Dayem[SUP] 5 [/SUP], Arooj K Qureshi[SUP] 1 [/SUP], Lok-Yin Roy Wong[SUP] 3 [/SUP], Jian Zheng[SUP] 3 [/SUP], David K Meyerholz[SUP] 6 [/SUP], Stanley Perlman[SUP] 3 [/SUP], Alimuddin Zumla[SUP] 7 8 [/SUP], Esam I Azhar[SUP] 1 2 [/SUP]
Affiliations
Abstract
Safe, passive immunization methods are required against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants. Immunization of chickens with antigen is known to induce specific IgY antibodies concentrated in the egg yolk and has a good safety profile, high yield of IgY per egg, can be topically applied, not requiring parenteral delivery. Our data provide the first evidence of the prophylactic efficacy of Immunoglobulin Y antibodies against SARS-CoV-2 in mice. Lohmann hens were injected with recombinant SARS-CoV-2 RBD protein; IgY-Abs were extracted from the eggs and characterized using SDS-PAGE. Antiviral activity was evaluated using plaque reduction neutralization tests. In additional experiments, IgY-RBD efficacy was examined in mice sensitized to SARS-CoV-2 infection by transduction with Ad5-hACE2 (mild disease) or by using mouse-adapted virus (severe disease). In both cases, prophylactic intranasal administration of IgY-Abs reduced SARS-CoV-2 replication, and reduced morbidity, inflammatory cell infiltration, hemorrhage, and edema in the lungs and increased survival compared to control groups that received non-specific IgY-Abs. These results indicate that further evaluation of IgY-RBD antibodies in humans is warranted.
. 2022 Sep 19;18(9):e1010782.
doi: 10.1371/journal.ppat.1010782. eCollection 2022 Sep.
SARS-CoV-2-specific immunoglobulin Y antibodies are protective in infected mice
Sherif A El-Kafrawy[SUP] 1 2 [/SUP], Abby Odle[SUP] 3 [/SUP], Aymn T Abbas[SUP] 1 2 4 [/SUP], Ahmed M Hassan[SUP] 1 [/SUP], Umama A Abdel-Dayem[SUP] 5 [/SUP], Arooj K Qureshi[SUP] 1 [/SUP], Lok-Yin Roy Wong[SUP] 3 [/SUP], Jian Zheng[SUP] 3 [/SUP], David K Meyerholz[SUP] 6 [/SUP], Stanley Perlman[SUP] 3 [/SUP], Alimuddin Zumla[SUP] 7 8 [/SUP], Esam I Azhar[SUP] 1 2 [/SUP]
Affiliations
- PMID: 36121829
- DOI: 10.1371/journal.ppat.1010782
Abstract
Safe, passive immunization methods are required against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants. Immunization of chickens with antigen is known to induce specific IgY antibodies concentrated in the egg yolk and has a good safety profile, high yield of IgY per egg, can be topically applied, not requiring parenteral delivery. Our data provide the first evidence of the prophylactic efficacy of Immunoglobulin Y antibodies against SARS-CoV-2 in mice. Lohmann hens were injected with recombinant SARS-CoV-2 RBD protein; IgY-Abs were extracted from the eggs and characterized using SDS-PAGE. Antiviral activity was evaluated using plaque reduction neutralization tests. In additional experiments, IgY-RBD efficacy was examined in mice sensitized to SARS-CoV-2 infection by transduction with Ad5-hACE2 (mild disease) or by using mouse-adapted virus (severe disease). In both cases, prophylactic intranasal administration of IgY-Abs reduced SARS-CoV-2 replication, and reduced morbidity, inflammatory cell infiltration, hemorrhage, and edema in the lungs and increased survival compared to control groups that received non-specific IgY-Abs. These results indicate that further evaluation of IgY-RBD antibodies in humans is warranted.